Abbott Synthroid
Executive Summary
Abbott submits NDA for thyroid hormone agent Synthroid two weeks ahead of FDA's Aug. 14 deadline for approved applications for levothyroxine products. Under an FDA guidance issued in July, Synthroid will be subject to phased-down production levels until the NDA is approved (1"The Pink Sheet" July 16, p. 16)